Aligos Therapeutics, Inc.(ALGS)

$5.77—

Chart

Aligos Therapeutics, Inc.(ALGS)

NASDAQ

$5.77—

Chart Studio

ALGS(ALGS)

ALGS

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-1.41

Aug 5, 2026 · Reports before open

Revenue Estimate

$16M

FY2030E EPS$1.48

Analyst Sentiment

Wall St. Consensus

Buy

5 analysts·Limited coverage

Score

3 Buy (60%)2 Hold (40%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

360%

Hold

240%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$20.00

+246.6%

Consensus

$20.00

+246.6%

Bull

$20.00

+246.6%

12-Month Target Range5 analysts

$20.00$20.00$20.00

Current $5.77Consensus

Current Price

$5.77

Upside to Consensus

$14.23

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-78.09%

EPS—

FY2028

Rev+1115.27%

EPS—

FY2029

Rev+241.90%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$20M	$4M	$52M	$178M	$237M
Low	$4M	$2M	$24M	$82M	$109M
High	$35M	$6M	$77M	$263M	$350M
EBITDA Avg	$-20M	$-4M	$-52M	$-178M	$-237M
Low	$-35M	$-6M	$-77M	$-263M	$-350M
High	$-4M	$-2M	$-24M	$-82M	$-109M
EBIT Avg	$-20M	$-4M	$-52M	$-178M	$-237M
Low	$-35M	$-6M	$-77M	$-263M	$-350M
High	$-4M	$-2M	$-24M	$-82M	$-109M
Net Income Avg	$-70M	$-44M	$-10M	$-3M	$15M
Low	$-79M	$-52M	$-73M	$-5M	$4M
High	$-62M	$-37M	$53M	$-876,604	$24M
EPS Avg	$-7.05	$-4.49	$-2.84	$-0.30	$1.48
Low	$-7.95	$-5.27	$-7.36	$-0.48	$0.44
High	$-6.29	$-3.70	$5.35	$-0.09	$2.39
Analysts (Rev / EPS)	4 / 5	4 / 5	4 / 5	3 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$600,000	$537,500	$275,000	$275,000	$275,000	$6M
Low	$600,000	$537,500	$275,000	$275,000	$275,000	$6M
High	$600,000	$537,500	$275,000	$275,000	$275,000	$6M
EBITDA Avg	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
Low	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
High	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
EBIT Avg	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
Low	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
High	$-600,000	$-537,500	$-275,000	$-275,000	$-275,000	$-6M
Net Income Avg	$-23M	$-20M	$-16M	$-12M	$-13M	$-11M
Low	$-31M	$-20M	$-16M	$-12M	$-13M	$-11M
High	$-15M	$-20M	$-16M	$-12M	$-13M	$-11M
EPS Avg	$-2.21	$-1.90	$-1.53	$-1.20	$-1.21	$-1.07
Low	$-2.95	$-1.90	$-1.53	$-1.20	$-1.21	$-1.07
High	$-1.45	$-1.90	$-1.53	$-1.20	$-1.21	$-1.07
Analysts (Rev / EPS)	6 / 3	5 / 1	3 / 1	3 / 1	3 / 1	3 / 1

Earnings Surprises

Recent Analyst Actions

May 21, 2026Cantor Fitzgerald

Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Target:$20.00

+257.1%from $5.60

Jan 7, 2026UBS

UBS Starts Aligos Therapeutics Inc. (ALGS) at Buy

Target:$20.00

+128.3%from $8.76

Jan 6, 2023Piper Sandler

Piper Sandler Upgrades Aligos Therapeutics to Overweight, Raises Price Target to $3

Target:$3.00

+146.9%from $1.22

Jan 6, 2023Jefferies

Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3

Target:$3.00

+203.0%from $0.99

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance